Friday, October 25, 2013 8:46:11 AM
By Zacks.com, October 23, 2013, 12:08:05 PM EDT
Eli Lilly & Company ( LLY ) reported third quarter 2013 adjusted earnings per share of $1.11, well above the Zacks Consensus Estimate of $1.05 and 41% above the year-ago earnings of 79 cents. Year-over-year growth was attributable to the strong performance of several key products, cost control, a lower tax rate as well as a lower share count.
Third quarter revenues increased 6% to $5.77 billion, marginally above the Zacks Consensus Estimate of $5.76 billion. Revenues increased despite the impact of the Zyprexa patent expiry due to the strong performance of key products.
Reported earnings (including special items) declined 6% to $1.11 per share in the third quarter of 2013.
Quarterly Details
Third quarter revenues increased 6% reflecting price increases (5%) and higher volume (3%) that were partially offset by unfavorable currency fluctuation (2%). The higher volume was mainly due to the strong performance of several products like Humalog, Alimta, Trajenta and Forteo and the Animal Health segment. This was partially offset by the loss of exclusivity for Zyprexa, which is facing competition from several generic players as well as volume declines for Cymbalta.
U.S. revenues grew 11% to $3.3 billion mainly due to price increases, especially for Cymbalta. Ex- U.S. revenues remained flat at $2.5 billion mainly due to the unfavorable impact of the depreciation of the Japanese yen.
During the third quarter, Zyprexa recorded a 26% decline in revenues, which came in at $278.7 million. U.S. revenues fell 51% due to lower prices. International revenues decreased 20%, mainly due to the loss of market exclusivity in major markets apart from Japan. Zyprexa sales in Japan were affected by the weakening yen.
Products which performed well in the third quarter included Alimta (up 7% to $690.5 million), Humalog (up 7% to $616 million), Cialis (up 9% to $526.7 million), Forteo (up 6% to $306.7 million) and Strattera (19% growth to $173.2 million) among others.
Cymbalta sales increased 11% to $1.4 billion. However, growth was driven mainly by price increases. With the Cymbalta patent expiry coming up (Dec 11), inventory levels were down both at the wholesale and retail channels. The company expects U.S. sales to drop to about $500 million in the fourth quarter.
Eli Lilly's Animal Health segment contributed $530.3 million (up 11%) to revenues. Sales benefited from the withdrawal of Merck's ( MRK ) food animal product from the U.S. market.
Effient revenues increased 14% to $124.9 million. While U.S. revenues grew 15% to $92.7 million, due to higher prices, ex- U.S. revenues increased 10% to $32.2 million driven by higher volume and favorable currency movement.
Expenses
Eli Lilly's adjusted operating expenses declined 2% to $3 billion. Research and development (R&D) expenses increased 3% to $1.4 billion. Marketing, selling and administrative expenses declined 6% to $1.7 billion reflecting the company's cost control efforts. The company has cut down its sales and marketing activities in the U.S. for Cymbalta and Evista, due to impending generic competition.
EPS Guidance Narrowed
Eli Lilly narrowed its 2013 earnings guidance to $4.10 to $4.15 per share (old guidance: $4.05 - $4.15 per share). Revenue guidance remained unchanged at $22.6 billion - $23.4 billion. The Zacks Consensus Estimate for earnings and revenues is currently $4.12 per share and $22.9 billion, respectively.
Eli Lilly continues to expect marketing, selling and administrative expenses of $7.0 - $7.2 billion and R&D expenses of $5.3 - $5.5 billion.
Eli Lilly will start buying back shares under its new $5 billion share repurchase program shortly.
Our Take
Eli Lilly's third quarter results were once again better-than-expected with products like Cialis, Humalog, Alimta, Forteo and the animal health segment managing to offset the negative impact of the genericization of Zyprexa.
Eli Lilly expects revenues to remain flat or increase by about 3.5% in 2013 despite the expected loss of U.S. exclusivity for Cymbalta later this year.
While revenues will be impacted by the loss of Cymbalta exclusivity and the loss of the 15% royalty on exenatide sales, products like Humalog, Humulin, Cialis, Strattera, Forteo, Alimta, Cymbalta (outside the U.S.), Effient, Tradjenta and Axiron, and the animal health segment should contribute to sales. Emerging markets, especially China, should also drive sales. However, revenue growth in Japan could be adversely affected by the weak yen.
Eli Lilly is also working on controlling costs. Earlier this year, Eli Lilly had announced a restructuring initiative to help lessen the impact of the upcoming loss of patent exclusivity for Cymbalta and Evista, changing consumer needs and the change in the U.S. healthcare environment.
Eli Lilly currently carries a Zacks Rank #3 (Hold).
Read more: http://www.nasdaq.com/article/earnings-beat-from-eli-lilly-again-analyst-blog-cm290621#ixzz2ijlrsl00
_______________________________________________________
LLY
Recent LLY News
- Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity • PR Newswire (US) • 04/17/2024 10:15:00 AM
- Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement • PR Newswire (US) • 04/16/2024 02:00:00 PM
- Cal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and More • IH Market News • 04/03/2024 11:12:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:27:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 08:24:43 PM
- More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study • PR Newswire (US) • 03/10/2024 08:00:00 PM
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab • PR Newswire (US) • 03/08/2024 11:45:00 AM
- Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care • PR Newswire (US) • 03/07/2024 01:00:00 PM
- Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/05/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:26:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:24:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:21:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:18:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:16:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:05:40 PM
- Lilly to Participate in Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/20/2024 03:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:05:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 08:05:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:44:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:43:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:41:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:38:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:36:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:34:21 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM